Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. Its lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. TTI-0102 has been developed to address the obstacles facing previous thiol-based drugs, their short half-lives and side effects. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism that eliminates the spike in the immediate release of cysteamine that is commonly linked to GI side effects. TTI-0102â€™s initial applications are for mitochondrial encephalopathy, lactic acidosis and stroke-like episodes, Leigh syndrome, Rett syndrome and pediatric Nonalcoholic steatohepatitis.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-07-20	$0.5500	-3.51%	13,500
26-07-17	$0.5700	+7.55%	3,000
26-07-16	$0.5300	0.00%	500
26-07-15	$0.5300	-7.02%	5,500

Delayed Quote Toronto S.E.

More quotes

Income Statement and Estimates

More financial data

Net sales - Rate of surprise

Company calendar

Market Closed - Toronto S.E. Other stock markets 11:57:02 2026-07-20 EDT			5-day change	1st Jan Change
0.5500 ^CAD	-3.51%		+3.77%	-15.38%

07-13	Thiogenesis Therapeutics Receives Fda Rare Pediatric Disease Designation for Tti-0102 for the Treatment of Leigh Syndrome	CI
07-13	Thiogenesis Therapeutics' Treatment For Leigh Syndrome Receives FDA Rare Pediatric Disease Designation	MT

Market Cap	28.51M 20.24M 17.74M 16.46M 15.13M 1.95B 28.93M 196M 76.77M 956M 75.99M 74.35M 3.3B	P/E 2024	-8.65x	P/E 2025	-4.25x
Enterprise Value	26.89M 19.09M 16.73M 15.53M 14.27M 1.84B 27.29M 185M 72.42M 902M 71.68M 70.13M 3.11B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	87.27%	Yield 2024 *	-	Yield 2025	-

07-13	Thiogenesis Therapeutics Receives Fda Rare Pediatric Disease Designation for Tti-0102 for the Treatment of Leigh Syndrome	CI
07-13	Thiogenesis Therapeutics' Treatment For Leigh Syndrome Receives FDA Rare Pediatric Disease Designation	MT
06-17	Thiogenesis Therapeutics Appoints Gilad Aharon to its Board	MT
06-17	Thiogenesis Therapeutics, Corp. Appoints Gilad Aharon to Its Board of Directors	CI
06-03	Thiogenesis Therapeutics, Corp. announced that it has received CAD 9.07185 million in funding	CI
05-25	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-11	Thiogenesis Therapeutics to Raise $8 Million Via a Non-Brokered Private Placement	MT
05-11	Thiogenesis Therapeutics, Corp. announced that it expects to receive CAD 8 million in funding	CI
04-30	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-29	Thiogenesis Therapeutics, Corp. Auditor Raises 'Going Concern' Doubt	CI
02-02	Thiogenesis Therapeutics, Corp. Provides Program Update	CI
01-23	Thiogenesis Therapeutics, Corp. Announces the Presentation of Interim Data from Its Phase 2 (Eu) Clinical Study of Tti-0102 in Patients with Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes At Mitocon 2026	CI
11-26	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

07-13	Thiogenesis Receives FDA Rare Pediatric Disease Designation for TTI-0102 for the Treatment of Leigh Syndrome	NE
06-17	Thiogenesis Appoints Dr. Gilad Aharon to Its Board of Directors	NE
06-03	Thiogenesis Closes Oversubscribed Non-Brokered Private Placement for Gross Proceeds of C$9.07 Million	NE
06-01	Thiogenesis Upsizes Non-Brokered Private Placement of Common Shares	NE
05-11	Thiogenesis Announces Non-Brokered Private Placement	NE

Thiogenesis Therapeutics, Corp. Stock

Stocks

TTI

CA88410L1022

Biotechnology & Medical Research

Valuation: Thiogenesis Therapeutics, Corp.

Chart: Thiogenesis Therapeutics, Corp.

Latest news : Thiogenesis Therapeutics, Corp.

Analysts' recommendations: Thiogenesis Therapeutics, Corp.

Press Releases: Thiogenesis Therapeutics, Corp.

Quotes and Performance

Course Extremes

Managers and Directors: Thiogenesis Therapeutics, Corp.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Net sales - Rate of surprise

1 day	-3.51%
1 week	+3.77%
Current month	+1.85%
1 month	-1.79%
3 months	-9.84%
6 months	-8.33%
Current year	-15.38%

1 week	0.55	0.57
1 month	0.53	0.57
Current year	0.44	0.66
1 year	0.44	0.87
3 years	0.44	1.06
5 years	0.38	1.06
10 years	0.38	1.06

Manager	Title	Age	Since
Patrice Rioux CEO	Chief Executive Officer	75	2022-03-30
Brook Riggins CEO	Chief Executive Officer	60	-

Director	Title	Age	Since
Christopher Starr CHM	Chairman	73	2022-03-30
Patrice Rioux BRD	Director/Board Member	75	2022-03-30
Brook Riggins BRD	Director/Board Member	60	2018-05-02

Date	Insider	Type	Main position	Quantity	% Market Cap.
6/1/26	W. Mullally	Sell	Director	150,000	0.2894%
9/11/25	W. Mullally	Option	Director	75,000	0.1702%
8/1/25	W. Mullally	Sell	Director	64,000	0.1453%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
THIOGENESIS THERAPEUTICS, CORP.	-3.51%	+3.77%	-32.93%	-15.38%	20.24M
LONZA GROUP AG	+1.64%	-5.29%	-4.52%	+12.21%	46.06B
REVOLUTION MEDICINES, INC.	-0.14%	-0.76%	+378.26%	+583.71%	38.91B
BEONE MEDICINES AG	+0.39%	+2.79%	+8.23%	+61.99%	35.57B
IQVIA HOLDINGS INC.	-1.54%	-4.01%	+5.95%	-13.03%	33.13B
CELLTRION, INC.	-0.87%	-3.19%	-1.27%	+29.16%	26.42B
ASCENDIS PHARMA A/S	-1.28%	-6.20%	-	-	16.61B
MEDPACE HOLDINGS, INC.	-0.67%	-0.21%	+10.55%	+115.31%	15.08B
EUROFINS SCIENTIFIC SE	-6.63%	-5.18%	+4.01%	+7.68%	14.08B
ICON PUBLIC LIMITED COMPANY	+0.40%	-2.79%	+3.58%	-31.98%	12.81B
Average	-1.22%	-2.20%	+41.32%	+83.30%	23.87B
Weighted average by Cap.	-0.46%	-2.60%	+68.57%	+122.73%

	2024	2025
Net sales	-	-
Net income	-3.15M -2.23M -1.96M -1.82M -1.67M -216M -3.19M -21.64M -8.47M -105M -8.38M -8.2M -364M	-7.43M -5.27M -4.62M -4.29M -3.94M -509M -7.54M -51.09M -20M -249M -19.79M -19.37M -860M
Net Debt	-3.85M -2.73M -2.39M -2.22M -2.04M -264M -3.9M -26.47M -10.36M -129M -10.26M -10.03M -446M	-1.62M -1.15M -1.01M -933K -858K -111M -1.64M -11.12M -4.35M -54.17M -4.31M -4.21M -187M